An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients
Cancer Treatment Communications
Castrate-resistant; Everolimus; Pasireotide; Phase II; Prostate cancer
© 2015 Elsevier Ltd. New areas of research continue to examine the role of non-androgen receptor pathways in prostate cancer treatment. The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway may be a target for prostate cancer therapy. Somatostatin receptor signaling inhibits intracellular PI3K/Akt signaling, making it an attractive target for combination therapy. We conducted a phase II open label clinical trial examining the use of somatostatin receptor agonist, pasireotide (SOM230) in combination with mTOR inhibitor, everolimus in metastatic castrate-resistant chemotherapy-naïve prostate cancer patients. Of the 6 patients enrolled in the study, only 1 patient had >50% PSA reduction from baseline. Three patients withdrew due to grade 3 adverse events. The study was closed early due to toxicity profiles and no further development was planned for this combination treatment in prostate cancer.
Lin, J., Deng, A., Hoffman-Censits, J., Gibney, G., Hyslop, T., Miller, B., Kilpatrick, D., Jabbour, S., & Kevin Kelly, W. (2015). An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients. Cancer Treatment Communications, 4 (). http://dx.doi.org/10.1016/j.ctrc.2015.11.003